Related Experiment Video
Updated: Jun 5, 2026
10:31
Three-dimensional Imaging and Analysis of Mitochondria within Human Intraepidermal Nerve Fibers
Published on: September 29, 2017
10.2K
Metabolomics in Pathogenic Pathways and Targeted Therapies for Diabetic Neuropathy: A Comprehensive Review
Cornelia Bala1, Adriana Rusu1, Dana Mihaela Ciobanu1
1Department of Diabetes and Nutrition Diseases, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania.
Metabolites
|February 25, 2025
Summary
Metabolomics reveals key metabolic changes in diabetic neuropathy (DN). While no biomarkers are clinically validated, promising treatments show potential for managing DN progression and improving patient outcomes.
Area of Science:
- Biochemistry
- Neuroscience
- Endocrinology
Background:
- Diabetic neuropathy (DN) is a significant complication of diabetes.
- Current diagnostic and prognostic tools for DN are limited.
- Metabolomics offers a novel approach to understand DN pathogenesis.
Purpose of the Study:
- To review the advancements in metabolomic assessments for diabetic neuropathy.
- To explore the utility of metabolomics in animal, cell, and human studies of DN.
- To identify potential biomarkers and therapeutic targets for DN.
Main Methods:
- Literature review of studies employing metabolomic analysis in DN.
- Analysis of metabolic alterations in various models and human subjects with DN.
- Evaluation of metabolomics-guided treatment strategies for DN.
Main Results:
- Diabetic neuropathy is associated with significant metabolic dysregulation, affecting energy metabolism, carbohydrates, lipids, amino acids, peptides, and proteins.
- Metabolomic profiling has identified potential biomarkers for DN.
- Several DN treatments show promise when assessed through metabolomic analysis.
Conclusions:
- Metabolomics holds potential for identifying individuals at risk of developing DN or its severe complications.
- Metabolites could serve as indicators for treatment response in clinical trials for DN.
- Further validation is needed for clinical application of metabolomic biomarkers in DN.
More Related Videos
Related Concept Videos
01:20Pathophysiology of Diabetes
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:22Diabetic Ketoacidosis ll: Pathophysiology
Diabetic ketoacidosis (DKA) is a metabolic emergency characterized by hyperglycemia, ketonemia, and metabolic acidosis. It results from severe insulin deficiency and an excess of counterregulatory hormones, leading to uncontrolled lipolysis, ketogenesis, and widespread electrolyte and fluid disturbances.Pathophysiology The central event in DKA is a profound loss of insulin action. Without insulin, glucose uptake in insulin-dependent tissues is impaired, while hepatic glucose production...
01:22Diabetic Neuropathy
DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...